好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Impact of Language Barriers on Acute Stroke Treatments
Cerebrovascular Disease and Interventional Neurology
P10 - Poster Session 10 (5:00 PM-6:00 PM)
13-006

To determine if non-English speaking patients experience delays in acute stroke intervention compared to English-speaking patients.

Disease-modifying treatment for stroke depends on rapid evaluation. Communication across language barriers may delay or impair obtaining accurate history, performing elements of the neurological exam, screening for contraindications, and assenting/consenting to treatment.

This is a retrospective study utilizing 305 patients who underwent acute stroke intervention (thrombolysis with alteplase or tenecteplase and/or mechanical thrombectomy) at two urban comprehensive stroke centers 2021-2023. We categorized each patient’s primary speaking language as English, Spanish, or Other. Linear regressions were performed to analyze the entire data set and treatment type subgroups. To account for other causes of treatment delay, we also included the following covariates: low National Institutes of Health Stroke Scale (NIHSS) (NIHSS<4), presence of peri-code medical events (intubation, nausea/vomiting, seizure, agitation), signs of hemodynamic instability, and medical comorbidities and demographic features

Median door-to-needle (DTN) time was 48 minutes. Median door-to-thrombectomy (DTT) time was 142 minutes. Language was associated with delayed DTT in the subset of patients who received both thrombolysis and thrombectomy (p=0.0147). Peri-code nausea/vomiting (p=0.0285), elevated blood pressure (p=0.0419), low NIHSS (p=0.0320), and history of atrial fibrillation (p=0.0331) were associated with longer DTN times in patients who underwent thrombolysis. In the subgroup of patients who underwent thrombolysis without thrombectomy, only a history of atrial fibrillation was associated with increased DTN time (p=0.0212).  Low NIHSS was associated with longer DTT times in all patients who underwent thrombectomy (p<0.001) and the subset of patients who underwent thrombectomy without thrombolysis (p<0.001).

Our study confirmed several factors known to delay acute stroke intervention, including language. We hypothesize that the impact of language on patients who receive both thrombolysis and thrombectomy is related to the increased communication needed to screen and consent for treatments.
Authors/Disclosures
Samantha J. Cheng, MD
PRESENTER
Dr. Cheng has nothing to disclose.
Sarah Wang, MD Dr. Wang has nothing to disclose.
Gautham V. Upadrasta, MD Dr. Upadrasta has nothing to disclose.
Austin M. Saline, MD Dr. Saline has nothing to disclose.
Liane E. Hunter, MD, PhD Dr. Hunter has nothing to disclose.
Michelle Ganat, MD (Montefiore Medical Center) Dr. Ganat has nothing to disclose.
Stella Iskandarian, MD (Montefiore Medical Center) Dr. Iskandarian has nothing to disclose.
Esther Levison, MD Dr. Levison has nothing to disclose.
Daniel L. Labovitz, MD An immediate family member of Dr. Labovitz has received personal compensation for serving as an employee of Herrick Feinstein.
Oleg Otlivanchik, MD (Montefiore Medical Center) Dr. Otlivanchik has nothing to disclose.
Charles Esenwa, MD (Montefiore Medical Center) Dr. Esenwa has nothing to disclose.
Lauren Gluck, MD (Montefiore Medical Center) Dr. Gluck has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeautics. Dr. Gluck has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Gluck has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen Rare Disease. Dr. Gluck has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Gluck has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb.